By means of X-ray crystallography and CA inhibition assays with hCAs I, II, IX and XII, a large number of ureidobenzenesulfonamide derivatives incorporating different R-ureido moieties have been tested for the selective binding to the enzyme (active site) of the tumour-associated over other CA isoforms [31]. The gene discussed is CYP24A1; the disease is neoplasm.